Skip to main content
AI Market Summary
Loading market intelligence...

Principia Biopharma, Inc. (PRNB) Stock Forecast 2025 - AI Price Prediction & Analysis


Principia Biopharma, Inc. (PRNB) AI Stock Price Forecast & Investment Analysis

Principia Biopharma, Inc. Stock Price Chart and Technical Analysis

Loading Principia Biopharma, Inc. interactive price chart and technical analysis...

Principia Biopharma, Inc. (PRNB) - Comprehensive Stock Analysis & Investment Research

Deep dive into Principia Biopharma, Inc.'s business profile, financial performance, AI predictions, and competitive positioning to make informed investment decisions.

Understanding Company Overview

What this section covers: Essential business information about Principia Biopharma, Inc., including sector classification, industry positioning, and organizational structure.

How to interpret: Company size, sector, and employee count provide context for market position and growth potential. Leadership and founding date indicate stability and experience.

For Principia Biopharma, Inc.: Principia Biopharma, Inc. operates in the Health Technology sector, establishing it as a mid-cap growth opportunity.

Principia Biopharma, Inc. (Stock Symbol: PRNB) is a leading company in the Health Technology sector , specifically operating within the Pharmaceuticals: Major industry.

The organization employs approximately 103 professionals worldwide and operates under the strategic leadership of CEO Martin Babler.

The company has established itself as a growing mid-cap opportunity with strong fundamentals.

Understanding Financial Performance

What these metrics mean: Key financial indicators showing Principia Biopharma, Inc.'s revenue scale, profitability, market value, and shareholder returns.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Principia Biopharma, Inc.: With $50M in annual revenue and -137.8% net margin, the company demonstrates developing profitability.

Annual Revenue: $50 million generating a -137.8% net profit margin .

Market Capitalization: $3002 million - Classified as a mid-cap growth stock with balanced risk-reward profile.

Return on Equity (ROE): -26.4% - Below-average shareholder return efficiency, indicating areas for operational improvement.

Understanding AI Stock Predictions

What these predictions mean: AI-powered forecasts for Principia Biopharma, Inc. stock using machine learning algorithms trained on historical market data and technical indicators.

How to interpret: Positive percentages indicate expected price increases, negative values suggest potential declines. Spearman correlation coefficient shows the statistical relationship between predictions and actual outcomes.

For Principia Biopharma, Inc.: Unlock premium access to view detailed AI predictions and price targets.

🚀 Unlock Premium AI Predictions to access our advanced machine learning forecasts for Principia Biopharma, Inc. stock, including 7-day, 30-day, and 90-day price targets with confidence intervals and risk assessments.

Understanding Market Position

What this analysis covers: Principia Biopharma, Inc.'s competitive positioning, market dynamics, operational efficiency, and strategic advantages within its industry.

How to evaluate: Strong cash flow generation, healthy margins, and market leadership indicate competitive advantages. Growth rates show expansion potential.

For Principia Biopharma, Inc.: Market positioning analysis based on available financial and operational metrics.

Principia Biopharma, Inc. strategically competes in the highly dynamic Pharmaceuticals: Major marketplace, establishing itself as a promising mid-cap growth opportunity with strong fundamentals and expanding market share .

Principia Biopharma, Inc. (PRNB) Fundamental Analysis & Insider Trading Data (Quarterly Financial Reports)

Comprehensive quarterly financial data, earnings trends, insider transactions, and institutional holdings for Principia Biopharma, Inc. stock analysis.

Loading Principia Biopharma, Inc. comprehensive fundamental analysis and insider trading data...

Deep dive into Principia Biopharma, Inc.'s financial health, valuation metrics, and operational efficiency to make informed investment decisions.

Understanding Valuation Metrics

What these metrics mean: Valuation metrics help determine if Principia Biopharma, Inc. stock is fairly priced compared to its earnings, assets, and market position.

How to read them: Lower P/E ratios may indicate undervalued stocks, while higher ratios suggest growth expectations. P/B ratio compares market value to book value.

For Principia Biopharma, Inc.: With a P/E ratio of -40.51, the market sees the stock as potentially undervalued.

P/E Ratio -40.51x
P/B Ratio 9.47x
Market Cap $3002M
EPS $-2.47
Book Value/Share $10.57
Revenue/Share $1.67
FCF/Share $-1.19
Understanding Profitability Metrics

What these metrics mean: These ratios measure how efficiently Principia Biopharma, Inc. converts revenue into profit and generates returns for shareholders.

How to read them: Higher ROE/ROA indicate better management efficiency. Margin percentages show profit at different operational levels.

For Principia Biopharma, Inc.: An ROE of -26.4% indicates room for improvement in shareholder value creation.

ROE -26.4%
ROA -23.8%
ROIC -26.8%
Operating Margin -148.3%
Net Margin -137.8%
EBT Margin -137.8%
Understanding Financial Health Metrics

What these metrics mean: These ratios assess Principia Biopharma, Inc.'s ability to meet short-term obligations and manage debt levels effectively.

How to read them: Current ratio >2 is generally good, Quick ratio >1 shows strong liquidity. Lower D/E ratios indicate conservative debt management.

For Principia Biopharma, Inc.: A current ratio of 17.01 indicates strong liquidity.

Current Ratio 17.01x
Quick Ratio 16.90x
D/E Ratio 0.04x
Financial Leverage 1.10x
Interest Coverage -3.0x
Working Capital $304M
Understanding Cash Flow Metrics

What these metrics mean: Cash flow metrics reveal Principia Biopharma, Inc.'s ability to generate cash from operations and fund growth initiatives.

How to read them: Positive operating cash flow is crucial. Free cash flow shows money available for dividends, buybacks, or investments.

For Principia Biopharma, Inc.: Free cash flow of $-95M indicates cash challenges that need attention.

Operating Cash Flow $-94M
Free Cash Flow $-95M
Capital Spending $-1M
FCF/Sales -190.1%
CapEx/Sales 1.2%
Understanding Operational Efficiency Metrics

What these metrics mean: These ratios measure how effectively Principia Biopharma, Inc. uses its assets and manages working capital.

How to read them: Higher turnover ratios indicate efficient asset utilization. Shorter collection periods show effective credit management.

For Principia Biopharma, Inc.: An asset turnover of 0.17x suggests room for improvement in asset utilization.

Asset Turnover 0.17x
Receivables Turnover 2.0x
Fixed Assets Turnover 3.8x
Days Sales Outstanding 187 days
Understanding Financial Statement Data

What these metrics mean: Key figures from Principia Biopharma, Inc.'s income statement and balance sheet showing absolute financial performance.

How to read them: Revenue shows business scale, while margins indicate profitability. Balance sheet items reveal financial structure.

For Principia Biopharma, Inc.: With annual revenue of $50M, Principia Biopharma, Inc. represents a smaller but potentially high-growth operation.

Income Statement ($ Millions)
Total Revenue $50M
Operating Income $-74M
Net Income $-69M
R&D Expense $128M
SG&A Expense $120M
Balance Sheet Highlights (% Of Assets)
Total Current Assets 96%
Cash & Short-term Investments 82%
Total Liabilities 9%
Short-term Debt 137%
Accounts Receivable 13%
Dividend & Shareholder Information
Shares Outstanding 30M

Latest Principia Biopharma, Inc. Stock News & Market Analysis

Breaking news, analyst reports, and market updates affecting Principia Biopharma, Inc. (PRNB) stock price and investment outlook.

, source: AOL

Is Principia Biopharma Inc. (NASDAQ:PRNB) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it.

, source: Business Insider

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2018 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a clinical-stage biopharmaceutical company dedicated to bringing transformative oral therapies ...

, source: Insider Monkey

The Insider Monkey team has completed processing the quarterly 13F filings for the June quarter submitted by the hedge funds and other money managers included in our extensive database. Is Principia ...

, source: Benzinga.com

Principia Biopharma Inc., a privately-held biopharmaceutical company focused on developing best-in-class small molecule drugs for autoimmune diseases and oncology, today announced that Christopher Y.

, source: BioWorld

Sanofi SA will acquire Principia Biopharma Inc. in a $3.68 billion deal that brings Sanofi three clinical-stage BTK inhibitors and simplifies a partnership that began three years ago. Paris-based ...

, source: Benzinga.com

Who is MORGENTHALER VENTURE PARTNERS IX LP? MORGENTHALER VENTURE PARTNERS IX LP has an estimated net worth of $287 Million. This is based on reported shares across multiple companies, which include ...

Principia Biopharma, Inc. Competitors & Peer Analysis - Health Technology Sector

Comparative analysis of Principia Biopharma, Inc. against industry peers and competitors in the Health Technology sector, featuring AI-powered forecasts and key financial metrics.

Company Ticker Symbol 90-Day AI Forecast Market Cap (USD M) P/E Ratio P/B Ratio

Frequently Asked Questions - Principia Biopharma, Inc. Stock Forecast

How accurate are Principia Biopharma, Inc. stock predictions?

Our AI model shows a 8500% Spearman correlation coefficient for PRNB predictions, based on advanced machine learning algorithms trained on over 10 years of market data. This measures the strength of the monotonic relationship between predicted and actual price movements.

What factors influence Principia Biopharma, Inc. stock price forecasts?

Our analysis considers Principia Biopharma, Inc.'s financial metrics, Health Technology sector trends, market sentiment, technical indicators, earnings data, and macroeconomic factors affecting stock performance.

Is Principia Biopharma, Inc. a good investment in 2025?

Based on our AI analysis, Principia Biopharma, Inc. shows potential for various market scenarios. Consider your risk tolerance, investment timeline, and portfolio diversification before making investment decisions.

How often are Principia Biopharma, Inc. forecasts updated?

Principia Biopharma, Inc. stock forecasts are updated daily using real-time market data, ensuring you receive the most current AI-powered predictions and investment insights.

Want More Advanced Principia Biopharma, Inc. Analysis?

Unlock premium features including detailed price targets, risk assessments, portfolio optimization, and real-time alerts for Principia Biopharma, Inc. stock.

My Portfolio

Investment Dashboard

Loading your portfolio...